Mechanisms of Action of the KCa2-Negative Modulator AP30663, a Novel Compound in Development for Treatment of Atrial Fibrillation in Man-Reference-Cited by-同舟云学术

Mechanisms of Action of the KCa2-Negative Modulator AP30663, a Novel Compound in Development for Treatment of Atrial Fibrillation in Man

Published:2020-05-06 Issue: Volume:11 Page:
ISSN:1663-9812
Container-title:Frontiers in Pharmacology
language:
Short-container-title:Front. Pharmacol.

Author:

Bentzen Bo Hjorth,Bomholtz Sofia Hammami,Simó-Vicens Rafel,Folkersen Lasse,Abildgaard Lea,Speerschneider Tobias,Muthukumarasamy Kalai Mangai,Edvardsson Nils,Sørensen Ulrik S.,Grunnet Morten,Diness Jonas Goldin

Funder

Wellcome Trust

Innovationsfonden

Horizon 2020

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference37 articles.

1. Late na(+) current inhibition by ranolazine reduces torsades de pointes in the chronic atrioventricular block dog model;Antoons;J. Am. Coll. Cardiol.,2010

2. Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent;Antzelevitch;J. Cardiovasc. Pharmacol. Ther.,2004

3. Electrophysiologic basis for the antiarrhythmic actions of ranolazine;Antzelevitch;Heart Rhythm.,2011

4. Role of late sodium channel current block in the management of atrial fibrillation;Burashnikov;Cardiovasc. Drugs Ther.,2013

5. A Novel Approach to High-Quality Postmortem Tissue Procurement: The GTEx Project;Carithers;Biopreserv. Biobank.,2015

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiac arrhythmogenesis: roles of ion channels and their functional modification;Frontiers in Physiology;2024-03-04

2. Dissecting the associations of KCNH2 genetic polymorphisms with various types of cardiac arrhythmias;Gene;2024-03

3. hiPSC-derived cardiomyocytes as a model to study the role of small-conductance Ca2+-activated K+ (SK) ion channel variants associated with atrial fibrillation;Frontiers in Cell and Developmental Biology;2024-01-18

4. A phase 1 trial of AP30663, a K_Ca2 channel inhibitor in development for conversion of atrial fibrillation;British Journal of Clinical Pharmacology;2024-01-08

5. Inhibition of the KCa2 potassium channel in atrial fibrillation: a randomized phase 2 trial;Nature Medicine;2023-12-13